Livagen for Health & Longevity

Evidence Review created on 08/31/2026 using AI4L / Opus 5

Also known as: KEDA, Lys-Glu-Asp-Ala, Lyvagen, H-Lys-Glu-Asp-Ala-OH

Motivation

Livagen is a laboratory-made chain of four amino acid building blocks, one of a family of very short peptides created in Russia from the 1970s onward on the idea that a small fragment copied from an organ’s own regulatory proteins can signal back to that organ and restore its youthful pattern of activity. Livagen was designed from liver tissue, and its proposed action is to loosen tightly packed regions of the cell’s genetic material so that genes switched off with age can be read again.

The wider family, usually called peptide bioregulators, has an unusual history: it grew out of Soviet military medicine, produced hundreds of publications and several products sold inside Russia, and has remained almost entirely separate from Western drug development. Livagen itself has never been given to people in a registered study, yet it is bought today by people pursuing a longer healthspan, almost always through unregulated online sellers.

This review examines what has actually been measured for Livagen, how far that evidence reaches, where it stops, and what the practical, sourcing and safety questions are for anyone weighing it.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Livagen

The only encyclopedic treatment of the compound, setting out its structure, Russian origins, chromatin and liver-protection research, and a candid section on regulatory status and the absence of independent replication.

Examine

No Examine article exists for Livagen. Examine covers supplements with a human evidence base; Livagen is sold only as a research-use-only chemical and has no human trials, placing it outside that scope.

ConsumerLab

No ConsumerLab article exists for Livagen. ConsumerLab tests retail supplements sold for human use; Livagen is not sold as a supplement in that market, so it has never been included in its testing programs.

Systematic Reviews

No systematic reviews or meta-analyses for Livagen were found on PubMed as of August 31, 2026.

Both sides of the trade-off are therefore unrepresented: no systematic review or meta-analysis exists for the claimed effect (chromatin reactivation and liver protection), and none exists for the principal risk (uncontrolled switching-on of silenced genes, and the product-quality hazards of unregulated supply).

Mechanism of Action

Livagen is the water-soluble tetrapeptide Lys-Glu-Asp-Ala (461.5 g/mol). Its proposed mechanism is epigenetic (acting on how genes are packaged, without changing the DNA sequence itself). Peptides this small are held to cross cell and nuclear membranes and bind DNA and histones (the spool proteins DNA winds around). The claimed effect is de-heterochromatinisation: unwinding of heterochromatin (densely packed, switched-off chromosome regions that accumulate with age, including pericentromeric regions near each chromosome’s centre), which reactivates ribosomal genes at the nucleolar organiser regions (the chromosome sites encoding protein-making machinery).

Two competing readings exist. The first is sequence-specific recognition: the peptide binds defined DNA switch sequences. The second is a non-specific charge effect: glutamate and aspartate weaken hydrogen bonding between DNA strands while lysine stabilises it, so any peptide of this composition could shift chromatin packing without tissue-specific information. Livagen has been mapped to no DNA motif, leaving the second reading open.

A better-defined action is enzyme inhibition: Livagen blocks human serum’s enkephalin-degrading enzymes (enkephalins are the body’s own pain-damping peptides) with an IC50 (the concentration halving enzyme activity) of 20 µM, without binding opioid receptors.

Pharmacological properties are largely unmeasured. No human half-life exists; the peptide resists breakdown for 3 to 4 hours in saline, gastric acid and tissue homogenate. Selectivity is inferred only from stimulated growth of liver explants (tissue fragments kept alive in a dish). Tissue distribution is unmeasured. Clearance is expected via peptidases (enzymes that cut peptides apart) rather than cytochrome P450 enzymes (the liver’s drug-metabolising system, including CYP3A4).

Historical Context & Evolution

Livagen’s original intended use was not longevity but organ repair. It descends from a classified Soviet military medical programme begun in the early 1970s that asked whether molecules extracted from an animal organ could restore the same organ in a person damaged by stress, injury or radiation. These extracts were named cytomedins (peptide fractions from a specific tissue). After 1992, at the St. Petersburg Institute of Bioregulation and Gerontology, each extract’s amino acid composition was analysed and a short peptide synthesised to reproduce it. Livagen is the synthetic counterpart of the liver fraction.

It came to be considered for health optimisation through one finding. In 2001 Livagen raised protein synthesis in cultured rat liver cells and restored its roughly hourly rhythm, most in cells from old animals; that same year it stimulated growth of liver explants but not brain or thymus explants. Chromatin work followed from 2002, enzyme and digestive studies from 2003 to 2005.

The evolution since is not one of consensus. Livagen never entered even Russian clinical practice, unlike the institute’s registered products, and its literature migrated to a Georgian genetics laboratory, where it became a reagent for probing aged chromatin rather than a therapy. The institute that generated this record also commercialises the peptide category, so its published position and its revenue point the same way. What changed instead is that Western demand arrived through gray-market longevity buying, and in July 2026 a United States advisory committee examined a sibling peptide, not Livagen, for regulated compounding.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: there is no human clinical endpoint and no validated clinical surrogate for Livagen in any trial, because the human-derived evidence consists entirely of cytogenetic assays on cultured white blood cells.

Medium 🟩 🟩

No benefit reaches Medium either: there is not one controlled human trial and not one observational cohort measuring a clinical outcome or validated surrogate, because the class of evidence available stops at animal organ measures and in-vitro enzyme assays.

Low 🟩

Speculative 🟨

Reactivation of Age-Silenced Chromatin ⚠️ Conflicted

In-vitro only: cultured white cells from donors aged 75–88 show looser chromosome packing and reactivated ribosomal genes. Earlier papers found pericentromeric decondensation, a later one none. Net: the nucleolar effect replicates, not the pericentromeric.

Liver Cell Protein Synthesis and Regeneration

Animal and tissue-explant data only: Livagen raised protein synthesis in rat liver cell cultures, most in old animals, restored its hourly rhythm, and stimulated growth of liver explants. No human liver measurement exists.

Liver Protection in Injury Models

Rodent models of acute hepatitis, chronic hepatitis and liver scarring only: a Russian review reports restored liver function with normalised immune and antioxidant status, largest in aged animals. No controlled human data exist.

Age-Dependent Normalisation of Digestive Enzyme Activity

Rat data only: two weeks of oral Livagen lowered gut enzyme activity in young animals and raised it in old ones toward young-animal levels. No human digestive measurement has been reported.

Protection Against Induced Chromosome Damage

In-vitro only: in white cells from aged donors Livagen cut cobalt-induced chromosome aberrations from 4.2% to 3.4%, corrected the radiation-induced adaptive response, and normalised instability markers in artery disease. No clinical endpoint measured.

Preservation of Endogenous Opioid Peptides

In-vitro only: Livagen inhibited the blood enzymes that degrade enkephalins, the body’s own pain-damping peptides, more potently than standard inhibitors, without binding opioid receptors. No symptom outcome was tested.

Benefit-Modifying Factors

Age: The single factor with a consistent signal. Effects on liver protein synthesis, digestive enzymes and chromatin packing were reported only, or largest, in aged animals and in donors aged 75 and above; young systems showed no benefit or the opposite direction.
Baseline biomarker levels: Every reported effect corrects a deviated baseline rather than enhancing a normal one. A person with normal liver enzymes, normal inflammatory markers and no measured epigenetic age acceleration has no deviation for Livagen to correct.
Genetic polymorphisms: No pharmacogenetic data exist for Livagen. Relevance would run through peptidase genes such as DPP4 (encoding an enzyme that clips short peptides in blood, setting clearance speed) and liver-disease modifiers such as PNPLA3 (a fat-handling gene affecting fatty liver risk).
Sex-based differences: None reported. Neither the animal work nor the human cell-culture work analysed results by sex, and the donor groups were not described by sex, so no sex-specific benefit or absence of benefit can be claimed in either direction.
Pre-existing health conditions: Liver injury is where the animal signal is strongest, with restored function reported in hepatitis and scarring models. Cell-level normalisation was also reported in donors with atherosclerosis (fatty plaque build-up in arteries) and hypertrophic cardiomyopathy (a thickened heart muscle disorder).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no human trial, no adverse-event surveillance database and no prescribing information exists for Livagen, because the class of evidence needed here, documented adverse events in people, has never been generated.

Medium 🟥 🟥

No risk reaches Medium either: no single human trial and no observational cohort has reported outcomes in Livagen users, because the only human-relevant evidence class available is indirect reporting on unregulated peptide products as a category.

Low 🟥

Harm from Unregulated, Unverified Product

Livagen reaches buyers only through research-chemical vendors. A 2026 narrative review of gray-market peptide use documents products of uncertain identity, purity, potency and sterility, alongside self-injection and stacking outside clinical supervision. The evidence is indirect, since no sampled product was Livagen, but the supply chain is the same one.

Magnitude: Not quantified in available studies. No surveillance system collects adverse events for research-use-only peptides, so no rate of contamination, mislabelling or injection-related infection has ever been measured for this product class.

Speculative 🟨

Uncontrolled Switching-On of Silenced Genes

Mechanistic only: the chromatin loosening framed as the benefit would, if real in a living body, also unsilence mobile genetic elements and cancer-promoting genes kept condensed with age. No tumour study exists.

Increased Sister Chromatid Exchange in Telomeric Regions

In-vitro only: combined with cobalt, Livagen raised sister chromatid exchanges (a marker of DNA strand breakage and repair) in chromosome-end regions to 12.0% against 2.8% in controls. Clinical meaning is unknown.

Reduced Digestive Enzyme Activity in Younger Users

Rat data only: two weeks of oral Livagen lowered intestinal and pancreatic enzyme activity in young animals, the opposite of its effect in old ones. No human digestive consequence has been examined.

Interference with Endogenous Opioid Signalling

In-vitro only: Livagen strongly inhibits enkephalin-degrading enzymes, so it could raise levels of the body’s own opioid peptides. Whether that alters mood, pain threshold or tolerance in people is untested.

Immune Reaction and Injection-Site Reactions

No published data exist for Livagen. Injected peptides can provoke antibody formation and local reactions, and no immune-reaction or injection-site assessment has been performed for this compound in humans or animals.

Risk-Modifying Factors

Cancer history: The proposed mechanism is gene switching-on, and the only measured DNA-damage signal is increased chromosome-end exchange. Anyone with current or prior malignancy carries a theoretical risk others do not, and no data exist to size it.
Age: Younger users sit in the worst position: the rat digestive-enzyme effect reverses, chromatin is not age-condensed, and heavy-metal-induced chromosome fragility was most inducible in young donors. At the older end, declining liver and kidney clearance raises exposure.
Pre-existing health conditions: Advanced liver disease reduces clearance capacity for any injected agent, and active autoimmune disease is a theoretical concern given the reported immune-modulating claims. Neither has been studied with Livagen in any species.
Baseline biomarker levels: Deranged baseline liver enzymes, elevated inflammatory markers or abnormal blood counts remove the ability to attribute any later change to Livagen rather than to the underlying condition, which is itself a safety problem.
Genetic polymorphisms: No data. Slow-clearance variants in peptidase genes such as DPP4 would raise exposure, and variants in DNA-repair genes such as BRCA1 (whose product repairs double-strand DNA breaks) would in theory amplify any DNA-damage signal.
Sex-based differences: None reported for risks. No study of Livagen in any species disaggregated adverse findings by sex, so a sex-specific hazard can neither be identified nor excluded.

Key Interactions & Contraindications

No interaction has ever been formally studied for Livagen; all entries below are mechanistic inferences, and each is labelled with its severity and the consequence it would produce.

Opioid analgesics and opioid antagonists (morphine, oxycodone, buprenorphine, naltrexone): Caution. Livagen inhibits enkephalin-breakdown enzymes, so it could add to or oppose opioid tone unpredictably. Mitigation: avoid initiating during opioid dose changes or opioid tapering.
Dipeptidyl peptidase-4 inhibitors (a class of diabetes drugs; sitagliptin, linagliptin, saxagliptin): Monitor. These block the same short-peptide-clipping enzymes that clear Livagen, so co-use could raise Livagen exposure. Mitigation: separate dosing by several hours and review blood glucose control.
Immunosuppressants (drugs that suppress the immune system; tacrolimus, ciclosporin, mycophenolate, prednisone): Caution. Livagen is claimed to modulate immune status, which could oppose intended suppression. Mitigation: avoid in transplant recipients, and do not adjust immunosuppressant dosing to accommodate it.
Over-the-counter medications — acetaminophen and high-dose non-steroidal anti-inflammatory painkillers (ibuprofen, naproxen): Monitor. Both load the liver, so concurrent use confounds any liver enzyme change and could mask injury. Mitigation: separate use and keep acetaminophen below 2 g daily.
Supplement interactions — other short peptide bioregulators (Epitalon, Vilon, Cortagen): Caution. These share the proposed chromatin mechanism, and stacking multiplies an unmeasured exposure. Mitigation: do not combine; the class was studied only as single agents.
Additive supplements — liver-support agents (milk thistle silymarin, N-acetylcysteine, tauroursodeoxycholic acid): Monitor. These act on the same liver enzyme readouts Livagen is claimed to improve, producing additive changes. Mitigation: hold additions constant so any signal is attributable.
Other intervention interactions — heavy metal exposure and metal-containing preparations: Caution. In cell studies Livagen combined with cobalt ions produced a chromosome-damage pattern different from either alone. Mitigation: avoid concurrent high-dose trace-metal supplementation.

Populations who should avoid Livagen:

Anyone with an active malignancy, or within 5 years of a solid-tumour or blood cancer diagnosis
Anyone with decompensated liver disease (Child-Pugh Class B or C, meaning moderate or severe loss of liver function)
Anyone with chronic kidney disease at stage 4 or worse (estimated glomerular filtration rate below 30 mL/min/1.73 m², a measure of filtering capacity)
Solid organ transplant recipients on maintenance immunosuppression
Pregnant or breastfeeding women
Anyone under 18 years of age
Anyone with known allergy to injected peptides or to benzyl alcohol preservatives
Anyone unable to obtain product with third-party identity, purity and sterility documentation

Risk Mitigation Strategies

Third-party certificate of analysis before use: A lot-specific report confirming the sequence by mass spectrometry, purity above 98%, and sterility and endotoxin results addresses the documented gray-market hazards of wrong identity, low potency and contamination.
Single-agent use with no stacking: Running Livagen alone rather than in a multi-peptide protocol avoids compounding unmeasured exposures and preserves the ability to attribute any adverse event or biomarker change to one compound.
Baseline and post-course laboratory panels: Liver enzymes, bilirubin, albumin and a blood count drawn before starting and 2 to 4 weeks after finishing address undetected liver injury and the marrow effects no trial has excluded.
Short bounded courses rather than continuous use: Exposure limited to a defined 10 to 20 day course with at least 3 months between courses addresses cumulative DNA-damage exposure, the risk least characterised by any existing study.
Current cancer screening before starting: Age-appropriate screening up to date, with no unexplained weight loss, node enlargement or new lesion, addresses the theoretical switching-on of cancer-promoting genes, the mechanism’s most serious unstudied consequence.
Stop rule defined in advance: Discontinuation on any rash, injection-site hardening, fever, yellowing of skin or eyes, or liver enzyme rise above three times the upper reference limit addresses delayed recognition of allergy, contamination and liver injury.

Therapeutic Protocol

No protocol for Livagen has been validated in any human study; what follows describes what practitioners and vendors in this field report doing, not an endorsement of any of it.

Cyclical short-course approach: The St. Petersburg Institute of Bioregulation and Gerontology, which sells this peptide category, popularised a 10 to 20 day course repeated two to three times yearly, rather than continuous daily use.
Oral route: Encapsulated bioregulators are typically taken at 1 to 2 capsules daily on an empty stomach for 10 to 30 days. Livagen resists intestinal breakdown, which is the stated rationale for oral use.
Injected route: Research-vendor material is supplied as 20 mg freeze-dried vials; reported subcutaneous use is 1 to 2 mg daily for 10 to 20 days. This route is favoured by Western longevity clinics rather than by the originating institute.
Competing approaches: The oral capsule course and the injected research-peptide course coexist with no comparative data. Neither is the default; the oral form has the longer use history, the injected form the higher delivered dose.
Best time of day: Morning dosing on an empty stomach is the common convention, tied to the reported restoration of an hourly protein-synthesis rhythm in liver cells. No timing study exists to support or refute it.
Half-life: No human half-life has been measured. In-vitro stability is 3 to 4 hours in saline, gastric acid and tissue homogenate, implying rapid clearance and no accumulation between daily doses.
Single versus split dosing: Given the short in-vitro stability, split dosing would be the pharmacologically coherent choice, yet every published animal protocol used once-daily administration. No comparison of the two has been made.
Genetic polymorphisms influencing dose: None established. Variants in peptidase genes such as DPP4 would in theory alter clearance, and liver-fat modifiers such as PNPLA3 would alter the target organ state, but no pharmacogenetic study exists.
Sex-based differences: No dose, response or efficacy difference by sex has been reported, because no study of Livagen in any species disaggregated its results by sex.
Age-related considerations: Reported effects were confined to, or largest in, aged systems. At the older end of the target range, reduced kidney and liver clearance argues for the lower end of any reported dose range rather than the upper.
Baseline biomarker levels: The reported effects are corrections of deviated values. Practitioners in this field select on elevated liver enzymes, raised inflammatory markers or accelerated epigenetic age, though no study has validated any of these as a response predictor.
Pre-existing health conditions: Liver disease is the condition the compound was designed around and where the animal signal is strongest. Cancer history, autoimmune disease and immunosuppression push in the opposite direction, toward exclusion rather than dose adjustment.

Discontinuation & Cycling

Not a lifelong intervention: Every published protocol in this class is a bounded course, not indefinite daily use. Nothing in the Livagen literature supports continuous administration, and no study has run longer than a few weeks of exposure.
Withdrawal effects: None reported. No study measured any outcome after stopping, so absence of reported withdrawal reflects absence of measurement rather than demonstrated absence of effect.
Tapering: No taper is described in any protocol, and none is pharmacologically indicated given clearance within hours and no receptor occupancy. Courses in this class are stopped abruptly on the scheduled end date.
Cycling for efficacy: Cycling is the norm rather than an option: two to three courses yearly with months between them. The stated rationale is avoiding tolerance and cumulative exposure, but no study has compared cycled with continuous dosing.
Deciding not to restart: No response marker has been validated, so restart decisions rest on whichever baseline abnormality prompted the first course. If that marker did not move, the honest reading is that no effect was demonstrated.

Sourcing and Quality

Regulatory status of supply: No pharmaceutical-grade Livagen exists anywhere. Every available source is a research-chemical vendor selling freeze-dried powder labelled not for human consumption, or a Russian or post-Soviet supplement brand outside Western regulatory oversight.
What to look for: A lot-specific certificate of analysis with mass spectrometry confirming the Lys-Glu-Asp-Ala sequence and a molecular weight of 461.5, chromatographic purity above 98%, and sterility and bacterial endotoxin results if the material is to be injected.
Third-party testing: Vendor-supplied documents are frequently generic rather than lot-specific. Independent testing of this product category routinely finds material that does not match its label, so a genuinely independent laboratory report is the only meaningful assurance.
Formulation considerations: Oral capsules from Russian bioregulator brands and injectable freeze-dried powder are not equivalent; the capsule products are peptide-complex blends rather than pure synthetic tetrapeptide. Reconstituted powder needs bacteriostatic water (sterile water with a preservative) and refrigeration.
Reputable sources: No brand or compounding pharmacy qualifies. Livagen was not among the substances considered for the United States 503A compounding list in July 2026, so no compounding pharmacy may lawfully prepare it, and no vendor has verifiable pharmaceutical manufacturing standards.

Practical Considerations

Time to effect: Unknown in humans. No human study has measured any outcome on any timescale. The cell and animal work reports changes over 1 to 14 days of exposure, which offers no basis for predicting a perceptible human effect.
Common pitfalls: Treating the chromatin findings as demonstrated human rejuvenation; stacking several bioregulators at once; using vendor certificates as independent verification; and running a course with no baseline measurement, which makes any later change uninterpretable.
Regulatory status: Not approved by the FDA or the European Medicines Agency for any indication, and not a registered medicine even in Russia. Sale is legal only as a research chemical; human use is entirely off-label and unsupervised.
Cost and accessibility: Not exceptionally expensive; a 20 mg research vial typically runs 40 to 90 US dollars, enough for one reported course. Accessibility is constrained instead by supply-chain legality and by verifying that the vial contains what the label claims.
Payer incentives: No insurer or health system pays for Livagen or any competing peptide bioregulator, so no institutional payer has reason to favour or disfavour it in guidelines. That same absence removes any payer incentive to fund the trials that would settle the question.

Interaction with Foundational Habits

Sleep: Direction is indeterminate. No sedative or stimulant property has been reported, and no sleep outcome has been measured. The one theoretical route runs through raised enkephalin levels, which could shift sleep architecture; morning rather than evening dosing is the practical hedge against that.
Nutrition: Direct and potentially blunting in younger users. Rat data show oral Livagen lowering intestinal and pancreatic enzyme activity in young animals, which would impair nutrient breakdown, and raising it in old ones. Adequate protein intake matters independently, since the claimed benefit is increased protein synthesis.
Exercise: No direct interaction identified, and no study has combined the two. Indirectly, the liver protein-synthesis findings would sit alongside rather than against resistance training. No blunting of muscle growth has been proposed or measured, and no timing convention exists.
Stress management: Indirect and potentially strengthening. The enkephalin-preserving action would in theory raise the body’s own opioid tone, which is one arm of the stress response, and the chromatin findings are framed against age-related and stress-related silencing. No cortisol or stress outcome has been measured.

Monitoring Protocol & Defining Success

Baseline testing matters more here than for an established agent, because there is no expected effect against which to judge a result. Before starting, a full liver panel, a complete blood count with differential, an inflammatory marker and iron stores establish both the safety limits and the deviated values a course is nominally aimed at. An epigenetic age estimate is taken at baseline because it is the outcome the proposed mechanism most directly predicts.

The practical ongoing cadence is a repeat liver panel and blood count 2 to 4 weeks after a course ends, then at 3 months, then every 6 to 12 months if courses continue. Inflammatory markers and iron stores follow the 3-month and annual timepoints; epigenetic age is interpretable only at 6 to 12-month intervals.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
ALT	10–26 U/L men, 10–19 U/L women	Detects liver cell injury, the target organ	Alanine aminotransferase, a liver-cell enzyme released on damage. Conventional labs flag only above 40–55 U/L, far above the functional target. Fasting not required; best paired with the aspartate aminotransferase and gamma-glutamyl transferase rows below
AST	10–26 U/L	Confirms whether an enzyme rise is liver or muscle	Aspartate aminotransferase, present in liver and muscle. Rises after hard exercise, so a sample taken within 48 hours of intense training is uninterpretable. Conventional cutoff is 40 U/L
GGT	Below 20 U/L men, below 15 U/L women	Most sensitive early marker of liver stress and bile flow	Gamma-glutamyl transferase, a bile-duct enzyme also reflecting oxidative load. Conventional ranges extend to 60–70 U/L. Alcohol raises it, so a valid result needs a 72-hour alcohol-free window before the draw
ALP	60–90 U/L	Flags bile duct obstruction and bone turnover	Alkaline phosphatase, a zinc-dependent enzyme. The conventional range of 40–130 U/L is wider at both ends. Values below 60 usually indicate zinc insufficiency rather than liver health
Total bilirubin	0.4–1.0 mg/dL	Reflects overall liver clearance capacity	A breakdown product of red blood cell pigment. Rises with fasting and with the harmless inherited Gilbert variant. Conventional upper limit is 1.2 mg/dL. Usually drawn fasting with the liver panel
Albumin	4.2–5.0 g/dL	Reflects the liver’s synthetic capacity, the function Livagen targets	The main blood protein made by the liver. The conventional lower limit of 3.5 g/dL misses early decline. Falls in inflammation, so it is interpreted alongside the inflammatory marker
hs-CRP	Below 0.5 mg/L	Tracks the inflammatory status the animal work claims is normalised	High-sensitivity C-reactive protein, a general marker of body-wide inflammation. The conventional cardiovascular cutoff of 3.0 mg/L is six times looser. Invalid within 2 weeks of infection or injury
Complete blood count with differential	Lymphocytes 1.5–3.0 ×10⁹/L, neutrophils 2.0–4.0 ×10⁹/L	Detects marrow effects no trial has excluded, and tracks the claimed immune effect	Lymphocytes and neutrophils are the two main white blood cell types. Conventional ranges are far wider, 1.0–4.8 and 1.8–7.7 ×10⁹/L respectively. Best paired with the inflammatory marker. A sustained drop below range during a course is a stop signal
Ferritin	50–100 ng/mL men, 30–80 ng/mL women	Iron overload is a common confounder of raised liver enzymes	An iron storage protein that also rises in inflammation. Conventional upper limits reach 300–400 ng/mL. Interpreted together with the inflammatory marker before a rise is attributed to iron
Epigenetic age acceleration	No established target exists for this measure; track the change from the individual’s own baseline instead	It is the outcome the proposed mechanism most directly predicts	A DNA methylation estimate of biological versus chronological age. Assay-to-assay variation is wide, so comparability requires the same laboratory and the same clock each time; drawn fasting

Qualitative markers are tracked alongside the laboratory values, since they are what a person actually notices:

Digestive comfort and tolerance of fat-rich or protein-rich meals, given the enzyme findings
Energy through the day, and whether any change tracks the course or its cessation
Sleep continuity and morning alertness
Cognitive clarity and sustained attention
Injection-site appearance, and any rash, itch or fever
Exercise recovery and perceived training capacity

Emerging Research

No registered trials of any kind: A ClinicalTrials.gov search on 31 August 2026 for Livagen, Lys-Glu-Asp-Ala and KEDA returned no studies, and searches for Epitalon, Epithalon, Thymalin and Cortexin returned none either. The entire class has zero registered interventional trials worldwide.
First independent replication in the class: Al-Dulaimi et al., 2025 at a United Kingdom laboratory found that the sibling tetrapeptide Epitalon lengthens telomeres (the protective caps on chromosome ends) in normal human cells. It is the first non-Russian confirmation of a measurable effect.
The same study is also the strongest counter-signal: In two breast cancer cell lines, Epitalon lengthened telomeres through alternative lengthening of telomeres (a repair route active in tumours). That is the class’s clearest mechanism-level warning, and it directly weakens the harmlessness assumption.
Continuing chromatin work: Lezhava et al., 2023 reported that each bioregulator selectively targets defined chromosome regions, but also that Livagen did not decondense pericentromeric heterochromatin, contradicting the same group’s earlier reports and leaving the core claim unsettled.
Regulatory re-examination of the class: At the July 2026 Pharmacy Compounding Advisory Committee meeting, a United States advisory panel reviewed Epitalon and six other peptides for possible addition to the 503A compounding list. Livagen was not among them, so its supply route remains unregulated regardless of that outcome.
The decisive unstudied question: No carcinogenicity or long-term toxicity study of Livagen exists in any species. A single rodent lifespan-and-tumour study would settle more than the entire existing chromatin literature has, and its absence after 25 years is itself informative.
Mechanism mapping remains empty: The 2021 systematic review of peptide gene regulation maps DNA-binding sites and histone contacts for several sibling peptides but names none for Lys-Glu-Asp-Ala, leaving Livagen without the sequence-specific evidence its tissue-specificity claim depends on.

Conclusion

Livagen is a four-unit peptide built in Russia from the amino acid make-up of a liver extract, on the theory that such a fragment can loosen the tightly packed genetic material of ageing cells and let switched-off genes work again. What has been measured supports interest, not confidence. In cells from people in their late seventies and eighties, and in old rats, it loosened chromosome packing, raised liver protein production, shifted digestive enzyme activity toward youthful levels, and blocked the enzymes that destroy the body’s own pain-damping peptides. None of that was measured as a health outcome in a living person, and no course has ever been given in a registered study.

The risks are unmeasured rather than reassuringly absent. The same loosening offered as the benefit would also switch back on genes that ageing cells keep shut for good reason, and a related peptide was recently shown to switch on a repair route used by tumour cells. The one risk with real-world evidence behind it is the supply itself, running entirely through unregulated sellers of uncertain identity and sterility.

The evidence base is also narrow at its source. Nearly all comes from the institute that designed the compound and profits from the peptide category, and the two outside accounts cited here both earn from continued interest in the peptide market. For someone prepared to act on early evidence, the honest position is that Livagen remains an unresolved question rather than a supported choice.

Top - Benefits - Risks - Protocol

Livagen for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Low 🟩

Speculative 🟨

Reactivation of Age-Silenced Chromatin ⚠️ Conflicted

Liver Cell Protein Synthesis and Regeneration

Liver Protection in Injury Models

Age-Dependent Normalisation of Digestive Enzyme Activity

Protection Against Induced Chromosome Damage

Preservation of Endogenous Opioid Peptides

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Harm from Unregulated, Unverified Product

Speculative 🟨

Uncontrolled Switching-On of Silenced Genes

Increased Sister Chromatid Exchange in Telomeric Regions

Reduced Digestive Enzyme Activity in Younger Users

Interference with Endogenous Opioid Signalling

Immune Reaction and Injection-Site Reactions

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion